Search by Drug Name or NDC

NDC 70510-2171-02 RADICAVA 30 mg/100mL Details

RADICAVA 30 mg/100mL

RADICAVA is a INTRAVENOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Mitsubishi Tanabe Pharma America, Inc.. The primary component is EDARAVONE.

MedlinePlus Drug Summary

Edaravone injection is used to treat amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease; a condition in which the nerves that control muscle movement slowly die, causing the muscles to shrink and weaken). Edaravone injection is in a class of medications called antioxidants. It may work to slow the nerve damage associated with the worsening of ALS symptoms.

Related Packages: 70510-2171-02
Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Edaravone Injection

Product Information

NDC	70510-2171
Product ID	70510-2171_d3d515d2-5301-4038-9eff-558de3b0e48d
Associated GPIs	74509030002010
GCN Sequence Number	077389
GCN Sequence Number Description	edaravone PIGGYBACK 30MG/100ML INTRAVEN
HIC3	H6I
HIC3 Description	AMYOTROPHIC LATERAL SCLEROSIS AGENTS
GCN	43378
HICL Sequence Number	044252
HICL Sequence Number Description	EDARAVONE
Brand/Generic	Brand
Proprietary Name	RADICAVA
Proprietary Name Suffix	n/a
Non-Proprietary Name	EDARAVONE
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	INJECTION
Route	INTRAVENOUS
Active Ingredient Strength	30
Active Ingredient Units	mg/100mL
Substance Name	EDARAVONE
Labeler Name	Mitsubishi Tanabe Pharma America, Inc.
Pharmaceutical Class	n/a
DEA Schedule	n/a
Marketing Category	NDA
Application Number	NDA209176
Listing Certified Through	2024-12-31

Package

NDC 70510-2171-02 (70510217102)

Pricing Information	N/A
NDC Package Code	70510-2171-2
Billing NDC	70510217102
Package	2 BAG in 1 CARTON (70510-2171-2) / 100 mL in 1 BAG (70510-2171-1)
Marketing Start Date	2017-05-05
NDC Exclude Flag	N